Dr Bing Wang - Researcher Profile

Biography

Dr Bing Hui Wang trained in Chemistry (BSc and MSc) and gained a PhD in the Department of Biochemistry, La Trobe University.  His post-doctoral research has been in the area of cellular signaling in cardiac vascular diseases. He was a senior research officer at the Baker Heart Research Institute for four years and involved in studies on the roles of adrenergic receptors in cardiac function and discovered inositol polyphosphate 1-phosphatase as a novel anti-hypertrophic factor.

He then changed his career to commercial research in biotechnology industry. During his research as the Senior Scientist and Head of the Molecular Biology Department, at Cytopia Pty Ltd he made substantial contributions to many of the patents and other intellectual properties.  

In October, 2005, Dr Wang re-joined academic research by taking up a Senior Research Fellow position with Prof Henry Krum, Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University. Under the mentorship of Prof Krum, Dr Wang has made significant progress and contribution to academic research in the areas of cardiovascular pharmacology, drug discovery and development, and cardiorenal syndrome research. Dr Wang has expertise in molecular and cellular biology, biomarkers and protein biochemistry, drug design and development, natural products chemistry and pharmacology, especially in signaling mechanisms of inflammatory cytokines and mediators/biomarkers in cardiovascular and renal diseases including heart failure and chronic kidney diseases.

Qualifications

DOCTOR OF PHILOSOPHY

Institution: La Trobe University

Year awarded: 1996

MASTERS DEGREE IN POLYMER CHEMISTRY

Institution: Fujian Normal University

Year awarded: 1991

BACHELOR OF SCIENCE

Institution: Xiamen University

Year awarded: 1984

Publications

Journal Articles

See, F., Watanabe, M., Kompa, A.R., Wang, B.H., Boyle, A., Kelly, D.J., Gilbert, R.E., Krum, H., 2013, Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction, Heart Lung and Circulation [P], vol 22, Elsevier Australia, Australia, pp. 122-132.

Zhang, Y., Elsik, M., Edgley, A.J., Cox, A., Kompa, A.R., Wang, B.H., Tan, C.Y., Khong, F.L., Stapleton, D.I., Zammit, S.C., Williams, S.J., Gilbert, R.E., Krum, H., Kelly, D.J., 2012, A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction, International Journal of Cardiology [P], vol e-pub, issue 1, Elsevier Ireland Ltd, Ireland, p. 12.

Liu, S., Wang, B.H., Kompa, A.R., Lekawanvijit, S., Krum, H., 2012, Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate, International Journal of Cardiology [P], vol epub, Elsevier Ireland Ltd, Ireland, pp. 457-458.

Liu, S., Lekawanvijit, S., Kompa, A., Wang, B., Kelly, D., Krum, H., 2012, Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins, Clinical and Experimental Pharmacology and Physiology [E], vol 39, issue 8, Wiley-Blackwell Publishing Asia, Australia, pp. 692-700.

Lekawanvijit, S., Kompa, A.R., Wang, B.H., Kelly, D.J., 2012, Cardiorenal syndrome: the emerging role of protein-bound uremic toxins, Circulation Research [P], vol 111, issue 11, Lippincott Williams & Wilkins, United States, pp. 1470-1483.

Lekawanvijit, S., Kompa, A.R., Manabe, M., Wang, B.H., Langham, R.G., Nishijima, F., Kelly, D.J., Krum, H., 2012, Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate, PLoS ONE [P], vol 7, issue 7 (Art. No: e41281), Public Library of Science, United States, pp. 1-9.

Zhang, Y., Edgley, A.J., Cox, A.J., Powell, A.K., Wang, B.H., Kompa, A.R., Stapleton, D.I., Zammit, S.C., Williams, S.J., Krum, H., Gilbert, R.E., Kelly, D.J., 2012, FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomypathy, European Journal of Heart Failure [P], vol 14, Oxford University Press, Netherlands, pp. 549-562.

Tan, S.M., Zhang, Y., Wang, B.H., Tan, C.Y., Zammit, S.C., Williams, S.J., Kelly, D.J., Krum, H., 2012, FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy, Clinical And Experimental Pharmacology And Physiology [P], vol 39, issue 8, Wiley-Blackwell Publishing Asia, Australia, pp. 650-656.

Lekawanvijit, S., Kompa, A., Zhang, Y., Wang, B., Kelly, D., Krum, H., 2012, Myocardial infarction impairs renal function, induces renal interstitial fibrosis and increases KIM-1 expression: Implications for the cardiorenal syndrome, American Journal of Physiology - Heart and Circulatory Physiology [E], vol epub, American Physiological Society, United States, pp. 1-11.

Wang, B.H., Reisman, S., Bailey, M., Kompa, A.R., Ayhan, M., Krum, H., Rice, G.E., 2012, Peptidomic profiles of post myocardial infarction rats affinity depleted plasma using matrix-assisted laser desorption/ionization time of flight (MALDI-ToF) mass spectrometry, Clinical and translational medicine [E], vol 1, issue Art. No: 11, SpringerOpen, United States, pp. 1-8.

Kompa, A., Wang, B., Xu, G., Zhang, Y., Ho, P., Eisennagel, S., Thalji, R., Marina, J., Kelly, D., Behm, D., Krum, H., 2012, Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction, International Journal of Cardiology [P], vol E, Elsevier Ireland Ltd, Ireland, pp. 1-10.

Tran, L., Kompa, A., Wang, B., Krum, H., 2011, Evaluation of the effects of Urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients, Cardiovascular Therapeutics [P], vol E, Wiley-Blackwell Publishing Ltd, UK, pp. 1-6.

Wang, B., Bertucci, M., Ma, J., Adrahtas, A., Cheung, R., Krum, H., 2010, Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone, Clinical And Experimental Pharmacology And Physiology [P], vol 37, issue 9, Wiley-Blackwell Publishing Asia, Australia, pp. 912-918.

Kompa, A., Wang, B., Phrommintikul, A., Ho, P., Kelly, D., Behm, D., Douglas, S., Krum, H., 2010, Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy, Peptides [P], vol 31, issue 8, Elsevier Inc, United States, pp. 1523-1530.

Tran, L., Kompa, A., Kemp, W., Phrommintikul, A., Wang, B., Krum, H., 2010, Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats, American Journal Of Physiology-Heart And Circulatory Physiology [P], vol 298, issue 2, American Physiological Society, United States, pp. 608-613.

Lekawanvijit, S., Adrahtas, A., Kelly, D., Kompa, A., Wang, B., Krum, H., 2010, Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?, European Heart Journal [P], vol 31, Oxford University Press, UK, pp. 1771-1779.

Phrommintikul, A., Tran, L., Kompa, A.R., Wang, B.H., Adrahtas, A., Cantwell, D., Kelly, D.J., Krum, H., 2008, Effects of a rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction, American Journal of Physiology: Heart and Circulatory Physiology, vol 294, issue 4, American Physiological Society, United States, pp. 1804-1814.

Kompa, A.R., See, F., Lewis, D., Adrahtas, A., Cantwell, D., Wang, B.H., Krum, H., 2008, Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction, Journal of Pharmacology and Experimental Therapeutics, vol 325, issue 3, American Society for Pharmacology and Experimental Therapeutics, United States, pp. 741-750.

Gao, X., Wang, B., Wang, B.H., Wang, B., Wang, B., Kiriazis, H., Su, Y., Dart, A.M., Du, X., Du, X., 2006, Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis, Journal of Hypertension, vol 24, issue 8, Lippincott Williams & Wilkins, Ltd, UK, pp. 1663-1670.

Woodcock, E.A., Wang, B.H., Arthur, J.F., Lennard, A., Matkovich, S.J., Du, X., Brown, J.H., Hannan, R.D., 2002, Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor, Journal of Biological Chemistry, vol 277, issue 25, American Society for biochemistry and Molecular Biology, Inc., USA, pp. 22734-22742.

Postgraduate Research Supervisions

Current Supervision

Program of Study:

(DOCTORATE BY RESEARCH).

Thesis Title:

Cardiorenal syndrome: pathophysiology and role of uremic toxins.

Supervisors:

Wang, B (Main), Kompa, A (Associate), Krum, H (Associate).

Completed Supervision

Student:

Tran, L.

Program of Study:

Urotensin II signalling pathway in cardiovascular disease. (PHD) 2011.

Supervisors:

Krum, H (Main), Kompa, A (Associate), Wang, B (Associate).